Canaccord Genuity analyst Matt Bottomley maintained a Buy rating on Columbia Care (OTC:CCHWF) on Friday, setting a price target of C$13, which is approximately 151.27% above the...
By Shariq Khan and Nichola Saminather TORONTO (Reuters) - Canadian and U.S. cannabis companies are facing a spike in already high costs of insurance to protect top executives from...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 373.28 | 377.55 | 366.93 | +5.47 | +1.49% | 29.68M | NASDAQ | |||
| 2,721.90 | 2,765.90 | 2,705.60 | +83.9 | +3.18% | 4.76M | NASDAQ | |||
| 196.01 | 198.00 | 189.76 | +9.94 | +5.34% | 34.54M | NYSE | |||
| 53.07 | 53.92 | 52.94 | -0.11 | -0.21% | 28.48M | NASDAQ | |||
| 43.45 | 43.74 | 42.25 | +1.35 | +3.21% | 53.82M | NYSE | |||
| 195.03 | 196.46 | 189.95 | +2.95 | +1.54% | 20.22M | NASDAQ | |||
| 10.29 | 10.29 | 10.11 | +0.08 | +0.78% | 3.60M | NYSE | |||
| 78.33 | 78.67 | 77.47 | +0.48 | +0.62% | 11.04M | NYSE | |||
| 38.90 | 39.56 | 36.08 | +0.89 | +2.34% | 71.02M | NYSE | |||
| 91.00 | 91.74 | 90.17 | -0.35 | -0.38% | 1.99M | NYSE | |||
| 3.00 | 3.095 | 2.93 | +0.080 | +2.74% | 721.68K | NASDAQ | |||
| 125.77 | 127.33 | 123.63 | +0.63 | +0.50% | 744.06K | NYSE | |||
| 86.23 | 87.26 | 83.00 | +2.74 | +3.28% | 339.16K | NASDAQ | |||
| 6.88 | 7.00 | 6.83 | -0.020 | -0.29% | 1.35M | NYSE | |||
| 141.77 | 143.10 | 141.64 | -0.98 | -0.69% | 2.54M | NYSE |
Columbia Care Inc is a provider of cannabis-based health and wellness solutions. The Company is engaged cultivating, manufacturing and providing medical and adult use cannabis products and related services with licenses in over 18 the United States jurisdictions and the European Union (EU). The Company operates facilities including dispensaries and cultivation and manufacturing facilities. The Company operates as the original providers of medical cannabis in the United States and continues to deliver a patient-centered medicinal cannabis operation. The company offers products spanning flower, edibles, oils, and tablets, and manufactures brands including Seed & Strain, Amber and Platinum Label Cannabidiol (CBD) products. It develops products which comprised of a variety of medical and adult-use form factors, including but not limited to formulations, precision manufactured dosing and cannabis flower and flower-derived products.
